Investigational Drug Information for Seladelpar
✉ Email this page to a colleague
What is the drug development status for Seladelpar?
Seladelpar is an investigational drug.
There have been 9 clinical trials for Seladelpar.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 21st 2021.
The most common disease conditions in clinical trials are Cholangitis, Liver Cirrhosis, Biliary, and Liver Diseases. The leading clinical trial sponsors are CymaBay Therapeutics, Inc. and [disabled in preview].
There are eighteen US patents protecting this investigational drug and three hundred and one international patents.
Summary for Seladelpar
| US Patents | 18 |
| International Patents | 301 |
| US Patent Applications | 128 |
| WIPO Patent Applications | 54 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2021-04-21) |
| Vendors | 36 |
Recent Clinical Trials for Seladelpar
| Title | Sponsor | Phase |
|---|---|---|
| An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | CymaBay Therapeutics, Inc. | Phase 1 |
| RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) | CymaBay Therapeutics, Inc. | Phase 3 |
| A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC | CymaBay Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for Seladelpar
Top disease conditions for Seladelpar
Top clinical trial sponsors for Seladelpar
US Patents for Seladelpar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Seladelpar | ⤷ Try a Trial | Combination therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| Seladelpar | ⤷ Try a Trial | Medical use of pharmaceutical combination or composition | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| Seladelpar | ⤷ Try a Trial | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome | Boehringr Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| Seladelpar | ⤷ Try a Trial | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | Janssen Pharmaceutical N.V. (Beerse, BE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Seladelpar
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Seladelpar | Australia | AU2011249722 | 2030-05-05 | ⤷ Try a Trial |
| Seladelpar | Brazil | BR112012028136 | 2030-05-05 | ⤷ Try a Trial |
| Seladelpar | Canada | CA2797310 | 2030-05-05 | ⤷ Try a Trial |
| Seladelpar | Canada | CA3070513 | 2030-05-05 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
